Information letter on Zelboraf®: Potentiation of radiation damage
2015.10.20
Active substance: vemurafenib
The company Roche Pharma AG is circulating information, that cases of severe radiation damage have been reported in patients treated with radiation prior to, during or subsequent to treatment with Zelboraf.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN